NCT07142057View on ClinicalTrials.gov

An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients

Not yet recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2030

Conditions
LUNG CANCER
Interventions
BIOLOGICAL

23-valent pneumococcal vaccine

Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine

All Listed Sponsors
lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER